Get the Stockscreener App
289.04
1.31%
-3.85
Insulet Corporation stock is traded at $289.04, with a volume of 895.77K.
It is down -1.31% in the last 24 hours and down -1.75% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$292.89
Open:
$293.08
24h Volume:
895.77K
Relative Volume:
1.40
Market Cap:
$20.33B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
87.96
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
+2.16%
1M Performance:
-1.75%
6M Performance:
-2.83%
1Y Performance:
+6.91%
1-Day Range:
$280.52
$294.04
1-Week Range:
$278.79
$299.80
52-Week Range:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
289.04 | 20.60B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Bernstein Lowers Price Target for Insulet (PODD) to $380, Mainta - GuruFocus
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD) - The Chronicle-Journal
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $365 From $388, Maintains Buy Rating - MarketScreener
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 - BioSpace
Is Insulet Corporation stock a bargain at current levelsJuly 2025 Market Mood & Daily Growth Stock Tips - ulpravda.ru
Will Insulet Corporation stock outperform value stocksEarnings Trend Report & Reliable Breakout Stock Forecasts - ulpravda.ru
Trading Recap: Why hedge funds are buying Insulet Corporation stockMarket Rally & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Institution Moves: What margin trends mean for Insulet Corporation stockGap Up & Safe Entry Trade Reports - ulpravda.ru
Pullback Watch: What margin trends mean for Insulet Corporation stockWeekly Trend Recap & Stock Market Timing Techniques - ulpravda.ru
Can Insulet Corporation stock hit record highs againTrade Entry Report & Technical Confirmation Alerts - ulpravda.ru
What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? - Insider Monkey
Can Insulet Corporation (GOV) stock resist broad market declinesWeekly Trading Summary & High Accuracy Investment Signals - ulpravda.ru
Insulet’s Human‑First Omnipod 5 CES Debut Might Change The Case For Investing In Insulet (PODD) - Sahm
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health - Business Wire
Declining Stock and Solid Fundamentals: Is The Market Wrong About Insulet Corporation (NASDAQ:PODD)? - Yahoo Finance
How Insulet Corporation (PODD) Affects Rotational Strategy Timing - Stock Traders Daily
Is it the Right Time to Add Insulet Stock to Your Portfolio? - Yahoo Finance
Will BluEnergies Ltd 66E stock benefit from infrastructure billJuly 2025 Update & Growth Focused Entry Reports - moha.gov.vn
Braun Stacey Associates Inc. Makes New Investment in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Insulet (PODD) - Zacks Investment Research
Insulet Corporation $PODD Shares Sold by Ayrshire Capital Management LLC - MarketBeat
From Edwards to Insulet: Three key medical device cases of 2025 - Life Sciences Intellectual Property Review
Insulet Corporation (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Swedbank AB Buys 5,000 Shares of Insulet Corporation $PODD - MarketBeat
Osaic Holdings Inc. Purchases 5,309 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Has $25.11 Million Stake in Insulet Corporation $PODD - MarketBeat
3 Reasons Growth Investors Will Love Insulet (PODD) - sharewise.com
Insulet Corporation $PODD Holdings Decreased by Squarepoint Ops LLC - MarketBeat
Insulet Corporation $PODD Shares Acquired by Munro Partners - MarketBeat
Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Patton Fund Management Inc. Buys 13,972 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corporation's (NASDAQ:PODD) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 - Insider Monkey
Is Insulet Fairly Priced After Its Strong Run and High Earnings Multiple in 2025? - simplywall.st
Voya Investment Management LLC Has $19.59 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
(PODD) Risk Channels and Responsive Allocation - Stock Traders Daily
Tubeless Insulin Pumps Market Size, Share, Trends | Top - openPR.com
Congress Asset Management Co. Acquires 9,976 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Why Insulet Corporation (GOV) stock is a strong analyst pick2025 Technical Patterns & AI Powered Market Entry Strategies - Улправда
Perpetual Ltd Sells 5,898 Shares of Insulet Corporation $PODD - MarketBeat
Should Insulet’s (PODD) Expanded Pod Recycling Effort Reframe Its Long‑Term Sustainability Edge? - Yahoo Finance UK
Guidance Update: Can Insulet Corporation (GOV) stock sustain revenue momentum2025 Growth vs Value & Weekly Breakout Watchlists - moha.gov.vn
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton By Investing.com - Investing.com Nigeria
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):